Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports. Yu ST, Huang D, Xiong C, Xie R, et al. Oral Oncol 2024;161:107140.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yu ST, Huang D, Xiong C, Xie R, et al. Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports. Oral Oncol 2024;161:107140.
PMID: 39693900